Summary
Biogen Inc. (BIIB) announced the completion of a significant debt offering, successfully issuing and selling $1.75 billion in aggregate principal amount of senior unsecured notes on May 12, 2025. This offering consists of three tranches: $400 million of 5.050% Senior Notes due 2031, $650 million of 5.750% Senior Notes due 2035, and $700 million of 6.450% Senior Notes due 2055. The company intends to use the net proceeds from this issuance, along with existing cash, to fully retire its outstanding $1.75 billion of 4.050% Senior Notes due 2025. This strategic refinancing aims to extend Biogen's debt maturity profile and potentially optimize its interest expense.
Key Highlights
- 1Biogen Inc. raised $1.75 billion through a new issuance of senior unsecured notes.
- 2The new debt consists of three tranches with varying maturities and coupon rates: 5.050% due 2031, 5.750% due 2035, and 6.450% due 2055.
- 3The primary use of proceeds is to fully redeem the outstanding $1.75 billion of 4.050% Senior Notes due 2025.
- 4This transaction effectively refinances the maturing debt, extending Biogen's debt maturity profile.
- 5The notes were issued under an automatic shelf registration statement filed on May 1, 2025.
- 6The notes include a change-of-control provision requiring a potential purchase offer at 101% of principal under certain circumstances.
- 7The remaining proceeds, if any, will be used for working capital and general corporate purposes.
Frequently Asked Questions
Biogen issued $1.75 billion in new senior unsecured notes primarily to refinance its maturing $1.75 billion of 4.050% Senior Notes due 2025. This move extends the company's debt maturity profile and ensures continued access to capital.
The new issuance comprises $1.75 billion in aggregate principal amount of senior unsecured notes, split into three series: $400 million of 5.050% Senior Notes due 2031, $650 million of 5.750% Senior Notes due 2035, and $700 million of 6.450% Senior Notes due 2055.
This issuance effectively replaces existing short-term debt (maturing in 2025) with longer-term debt obligations. While the principal amount remains $1.75 billion, the coupon rates on the new notes are generally higher than the maturing notes, indicating a potential increase in future interest expense, but with a significantly extended maturity.
Yes, the notes contain a change-of-control provision. If a change of control event occurs under certain circumstances, Biogen may be required to offer to purchase these notes at 101% of their principal amount, plus accrued interest.